Glutathione plays a central role in maintaining cellular redox homeostasis, and modulations to this status may affect malaria parasite sensitivity to certain types of antimalarials. In this study, we demonstrate that inhibition of glutathione biosynthesis in the Plasmodium berghei ANKA strain through disruption of the ␥-glutamylcysteine synthetase (␥-GCS) gene, which encodes the first and rate-limiting enzyme in the glutathione biosynthetic pathway, significantly sensitizes parasites in vivo to pyrimethamine and sulfadoxine, but not to chloroquine, artesunate, or primaquine, compared with control parasites containing the same pyrimethamine-resistant marker cassette. Treatment of mice infected with an antifolate-resistant P. berghei control line with a ␥-GCS inhibitor, buthionine sulfoximine, could partially abrogate pyrimethamine and sulfadoxine resistance. The role of glutathione in modulating the malaria parasite's response to antifolates suggests that development of specific inhibitors against Plasmodium ␥-GCS may offer a new approach to counter Plasmodium antifolate resistance.
Malaria causes approximately 438,000 deaths from 214 million cases annually (1). As no effective vaccine is yet available, chemotherapy is relied upon to combat the disease. However, Plasmodium falciparum has become resistant to all front-line antimalarial drugs in current use, such as chloroquine (2), combination sulfadoxine-pyrimethamine (Fansidar) (3, 4) and, most worrying, artemisinin and its analogs (5-9). Thus, new strategies are needed to counter drug resistance in Plasmodium.Among the various metabolic pathways in Plasmodium, antioxidant systems are likely to be involved in drug sensitivity as they maintain redox homeostasis and counter oxidant stress triggered by antimalarials (10, 11). Glutathione (GSH) is a major antioxidant in Plasmodium (12, 13). De novo GSH biosynthesis consists of two steps: (i) production of ␥-glutamylcysteine (␥-GC) from glutamic acid and cysteine by the rate-limiting ␥-glutamylcysteine synthetase (␥-GCS) and (ii) production of GSH from ␥-GC and glycine by glutathione synthetase (14, 15). Levels of intracellular GSH content and expression of GSH biosynthetic genes have been shown to correlate with artemisinin and chloroquine sensitivity (10,(16)(17)(18). However, knocking out or overexpressing the ␥-gcs gene in Plasmodium berghei does not alter chloroquine or artemisinin sensitivity but rather affects the ability of the parasite to recrudesce after artemisinin treatment (19).The effect of GSH on modulating Plasmodium sensitivity to other antimalarials is unclear. In this study, we investigated whether inhibiting GSH biosynthesis by genetically disrupting ␥-gcs or by using a ␥-GCS inhibitor would alter P. berghei sensitivity to other standard antimalarials, such as pyrimethamine, sulfadoxine, and primaquine.
MATERIALS AND METHODSP. berghei infection of mice. Six-to 10-week-old female BALB/c mice, purchased from the National Laboratory Animal Center, Mahidol University, Thailand, were used for P. berghe...